Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids for Treatment of Minnesota High-Risk Acute GVHD (aGVHD): A Phase I/II Study

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Methylprednisolone (Primary) ; NTx 265 (Primary) ; Prednisone (Primary) ; Ruxolitinib (Primary)
Indications Graft-versus-host disease
Focus Adverse reactions; Therapeutic Use

21 Oct 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2025.
12 Jun 2023 Status changed from not yet recruiting to recruiting.
01 May 2023 Planned initiation date changed from 1 Mar 2023 to 1 Jun 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com